Cytokinetics, Incorporated

DB:KK3A Stock Report

Market Cap: €5.4b

Cytokinetics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:KK3A Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
10 Dec 24Sell€96,417Fady MalikIndividual2,000€48.21
26 Nov 24Sell€95,767Fady MalikIndividual2,000€47.88
12 Nov 24Sell€57,432Fady MalikIndividual1,042€55.12
30 Oct 24Sell€95,634Fady MalikIndividual2,000€47.82
15 Oct 24Sell€99,403Fady MalikIndividual2,000€49.70
01 Oct 24Sell€94,152Fady MalikIndividual2,000€47.08
17 Sep 24Sell€102,111Fady MalikIndividual2,000€51.06
03 Sep 24Sell€107,636Fady MalikIndividual2,084€51.65
20 Aug 24Sell€101,293Fady MalikIndividual2,000€50.65
06 Aug 24Sell€98,239Fady MalikIndividual2,000€49.12
23 Jul 24Sell€105,054Fady MalikIndividual2,000€52.53
10 Jul 24Sell€287,528Robert BlumIndividual5,733€50.15
09 Jul 24Sell€103,408Fady MalikIndividual2,000€51.70
05 Jul 24Sell€12,762Robert HarringtonIndividual253€50.44
01 Jul 24Sell€579,681Robert BlumIndividual11,500€50.41
25 Jun 24Sell€100,419Fady MalikIndividual2,000€50.21
17 Jun 24Sell€1,103,630Robert BlumIndividual22,500€49.05
11 Jun 24Sell€116,975Fady MalikIndividual2,366€49.44
10 Jun 24Sell€96,934Muna BhanjiIndividual2,000€48.47
03 Jun 24Sell€584,209Robert WongIndividual13,011€44.90
03 Jun 24Sell€70,596Robert HarringtonIndividual1,580€44.68
09 Apr 24Sell€273,854Fady MalikIndividual4,000€68.46

Insider Trading Volume

Insider Buying: KK3A insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of KK3A?
Owner TypeNumber of SharesOwnership Percentage
State or Government46,1320.0333%
Private Companies105,8840.0765%
Individual Insiders580,7860.42%
Institutions137,653,87499.5%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.4%.

Top Shareholders

Top 25 shareholders own 85.81% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.9%
BlackRock, Inc.
15,252,839€692.8m3.95%0.01%
10.9%
T. Rowe Price Group, Inc.
12,854,932€583.9m22.5%0.05%
10.3%
FMR LLC
12,093,859€549.3m4.95%0.03%
9.97%
The Vanguard Group, Inc.
11,761,605€534.2m2.83%0.01%
6.59%
Wellington Management Group LLP
7,774,970€353.2m3.53%0.06%
5.47%
State Street Global Advisors, Inc.
6,458,324€293.4m-1.38%0.01%
3.97%
Bank of America Corporation, Asset Management Arm
4,687,476€212.9m10.5%0.07%
2.41%
Geode Capital Management, LLC
2,848,584€129.4m4.01%0.01%
2.31%
RTW Investments, LP
2,721,158€123.6m0%1.89%
1.98%
Polar Capital Holdings Plc
2,337,847€106.2m-4.76%0.4%
1.78%
Tavistock Life Sciences
2,100,000€95.4m0%7.01%
1.77%
Pictet Asset Management Limited
2,088,567€94.9m18.1%0.09%
1.61%
Armistice Capital LLC
1,896,575€86.1m-8.2%2.16%
1.59%
Marshall Wace LLP
1,873,701€85.1m11.7%0.13%
1.49%
PFM Health Sciences, LP
1,757,192€79.8m0%5.56%
1.41%
AllianceBernstein L.P.
1,661,014€75.4m-11.6%0.02%
1.27%
Vestal Point Capital, LP
1,500,000€68.1m-27.7%5.77%
1.13%
Northern Trust Global Investments
1,329,654€60.4m3.64%0.01%
1.12%
Charles Schwab Investment Management, Inc.
1,321,391€60.0m42.8%0.01%
1.03%
Westfield Capital Management Company, L.P.
1,212,886€55.1m38.9%0.24%
1.03%
Melqart Asset Management (Uk) Ltd
1,212,258€55.1m-27.7%7.29%
0.99%
Brown Advisory Incorporated
1,165,432€52.9m52.9%0.07%
0.97%
Janus Henderson Group plc
1,143,830€52.0m17.2%0.02%
0.94%
Sarissa Capital Management LP
1,110,000€50.4m0%13.3%
0.93%
Pentwater Capital Management LP
1,100,000€50.0m-1.7%1.04%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 13:42
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cytokinetics, Incorporated is covered by 36 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Carter GouldBarclays
Jason ZemanskyBofA Global Research
Mayank MamtaniB. Riley Securities, Inc.